Want to see MBX full AI Analyst Report?
MBX Biosciences, Inc. (MBX) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Mbx 4291 | Obesity | Phase I | Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity | Aug 04, 2025 | ― |
| Mbx 1416 (Inn Imapextide) | Postbariatric Hypoglycemia | Phase II | Recruiting | Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI) | Jun 11, 2025 | ― |
| 400 Μg Of Mbx 2109 Once-Weekly By Subcutaneous Injection, 200-1600 Μg Of Mbx 2109 Once-Weekly By Subcutaneous Injection | Hypoparathyroidism | Phase II | Recruiting | Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism | Jul 16, 2024 | ― |
| Mbx 2109 | Hypoparathyroidism | Phase II | Active Not Recruiting | Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism | Jun 13, 2024 | ― |
| Mbx 1416 (Part A), Mbx 1416 (Part B), Mbx 1416 (Part C) | Postbariatric Hypoglycemia | Phase I | Completed | Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects | Aug 28, 2023 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Mbx 4291 | Phase I | Obesity | Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity | Aug 04, 2025 | ― |
| Mbx 1416 (Inn Imapextide) | Phase II | Postbariatric Hypoglycemia | Recruiting | Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI) | Jun 11, 2025 | ― |
| 400 Μg Of Mbx 2109 Once-Weekly By Subcutaneous Injection, 200-1600 Μg Of Mbx 2109 Once-Weekly By Subcutaneous Injection | Phase II | Hypoparathyroidism | Recruiting | Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism | Jul 16, 2024 | ― |
| Mbx 2109 | Phase II | Hypoparathyroidism | Active Not Recruiting | Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism | Jun 13, 2024 | ― |
| Mbx 1416 (Part A), Mbx 1416 (Part B), Mbx 1416 (Part C) | Phase I | Postbariatric Hypoglycemia | Completed | Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects | Aug 28, 2023 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does MBX Biosciences, Inc. (MBX) have in its pipeline
MBX Biosciences, Inc. MBX is currently developing the following drugs: Mbx 4291, Mbx 1416 (Inn Imapextide), 400 Μg Of Mbx 2109 Once-Weekly By Subcutaneous Injection, 200-1600 Μg Of Mbx 2109 Once-Weekly By Subcutaneous Injection, Mbx 2109, Mbx 1416 (Part A), Mbx 1416 (Part B), Mbx 1416 (Part C). These drug candidates are in various stages of clinical development as the company works toward FDA approval.